Novartis Stock Rises 2.19 on Pipeline Advances and Strategic Deals Trading Volume Ranks 398th at 280 Million

On August 4, 2025, Novartis (NVS) rose 2.19% with a trading volume of $280 million, ranking 398th in the market. The stock’s performance followed key developments in its therapeutic pipeline and strategic partnerships.

The FDA approved a label expansion for Leqvio® (inclisiran), allowing its use as a monotherapy for reducing LDL cholesterol in adults with hypercholesterolemia. The decision, driven by robust data on PCSK9-targeting therapies, strengthens Novartis’s position in cardiovascular care.

Novartis also announced a collaboration with Matchpoint Therapeutics to develop oral inhibitors for inflammatory diseases, with potential total payments of up to $1 billion. The deal underscores the company’s focus on expanding its pipeline in immuno-inflammatory indications.

Recent clinical trial reports highlighted Novartis’s involvement in global studies for renal failure, multiple sclerosis, systemic lupus erythematosus, and other diseases. These initiatives reflect the company’s broad portfolio and ongoing investment in late-stage development programs.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.